CSPC Innovation Included in FTSE Global Equity Index Series

March 15, 2024

Recently, FTSE Russell (UK) published the Semi-annual Index Review Report of FTSE Global Equity Index Series. The report shows that 76 A-shares will be included in FTSE Global Equity Index Series.

CSPC Innovation (stock name: XNW, stock code: 300765.SZ), a subsidiary of CSPC Pharmaceutical Group Limited, is listed.

Founded in 1984 in London, United Kingdom, FTSE Russell is a wholly-owned subsidiary of the London Stock Exchange Group (LSEG). It is also a world-renowned index provider, alongside MSCI. FTSE Russell's index products cover more than 70 countries and regions worldwide. About USD 20 trillion of assets have been invested against these index products.

The adjustment will take effect on March 4. After adjustment, the number of constituent stocks of FTSE China A All Cap (Stock Connect) Index will increase from 1898 to 1973.

The inclusion of CSPC Innovation in FTSE Global Equity Index Series represents a key recognition of the capital market performance and importance of CSPC Innovation by internationally renowned index providers, marking another success after its inclusion by MSCI in MSCI China A Share Index on November 15, 2023.

Founded in 2006, CSPC Innovation is a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (CSPC) as the constituent stock of Hong Kong's Hang Seng Index (stock code: 1093.HK). CSPC Innovation landed on the A-share Growth Enterprise Market in 2019, becoming the first stock that a red chip company spins off its subsidiary to list on the A-share market in China. CSPC Innovation also represents an important arrangement in the A-share market.

Since the landing, CSPC Innovation has shown good corporate growth, steadily consolidated the performance basis, and continuously absorbed CSPC's quality assets to maximize the interests of shareholders.

· In 2022, CSPC Innovation acquired 100% stock equity of CSPC Shengxue Glucose Co., Ltd., expanding its business in the field of "big health".

· In September 2023, CSPC Innovation announced a cash capital increase to CSPC Megalith Biopharmaceutical Co., Ltd. to obtain 51% stock equity. Afterwards, CSPC Innovation developed into an innovative company that integrated R&D, production, and sales of biopharmaceuticals, functional foods, and raw materials.

· On January 11, 2024, CSPC Innovation announced that the company was planning to purchase 100% stock equity of CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. After the completion of the acquisition, CSPC Innovation will continue to expand its comprehensive strength in the bio-pharmaceutical field and strengthen and accelerate its transformation into an innovative biopharmaceutical enterprise.

Overall, CSPC Innovation will continue to focus on innovation, consolidate its main business, and pursue deeper development in the "big health" field with biopharmaceuticals and functional foods (raw materials). In addition, CSPC Innovation will strive to enhance its core competitiveness, make excellent performance to reward shareholders, and supply innovative drugs with more scientific and technological content to protect the lives and health of the people.

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |